| Literature DB >> 27884116 |
Agnieszka Perkowska-Ptasinska1, Dominika Deborska-Materkowska2, Artur Bartczak3, Tomasz Stompor4, Tomasz Liberek5, Barbara Bullo-Piontecka5, Anna Wasinska6, Agnieszka Serwacka6, Marian Klinger7, Jolanta Chyl8, Michal Kuriga9, Robert Malecki10, Krzysztof Marczewski11, Bogdan Hryniewicz12, Tadeusz Gregorczyk13, Monika Wieliczko14, Stanislaw Niemczyk15, Olga Rostkowska2, Leszek Paczek16, Magdalena Durlik2.
Abstract
BACKGROUND: Longer life expectancy is associated with an increasing prevalence of kidney disease. Aging itself may cause renal damage, but the spectrum of kidney disorders that affect elderly patients is diverse. Few studies, mostly form US, Asia and West Europe found differences in the prevalence of some types of kidney diseases between elderly and younger patients based on renal biopsy findings, with varied proportion between glomerulopathies and arterionephrosclerosis as a dominant injury found. Here, for the first time in Eastern Europe we analyzed native kidney biopsy findings and their relationship to clinical characteristics at the time of biopsy in elderly individuals (aged ≥65) in comparison to younger adults (aged 18-64).Entities:
Keywords: Glomerulonephritis; Hypertensive nephropathy; Kidney biopsy; Kidney disease in elderly
Mesh:
Year: 2016 PMID: 27884116 PMCID: PMC5123353 DOI: 10.1186/s12882-016-0410-8
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Clinical characteristics at the time of biopsy by age
| Elderly (aged ≥65) ( | Younger (aged 18–64) ( |
| |
|---|---|---|---|
| Male/female ratio | 1:1 | 1.1/1 | |
| Age of disease onset | median: 69 (range: 19–87) | median: 37 (range: 1–64) | <0.001 |
| Pre-biopsy follow-up (months) | median: 5 (range: 0–660) | median: 10 (range: 0–612) | <0.001 |
| Pre-biopsy follow-up | |||
| <3 months | 165 (46.9%) | 848 (38.3%) | 0.002 |
| Proteinuria | |||
| nephrotic | 188 (55.6%) | 916 (42.8%) | <0.001 |
| Hematuria | 159 (45.3%) | 1359 (61.8%) | <0.001 |
| Nephrotic range proteinuria without hematuria | 115 (34.2%) | 453 (21.3%) | <0.001 |
| Non-nephrotic proteinuria with hematuria | 76 (22.5%) | 787 (37%) | |
| Nephrotic range proteinuria with hematuria | 73 (21.6%) | 461 (21.6%) | |
| Non-nephrotic proteinuria without hematuria | 58 (17.2%) | 328 (15.4%) | |
| Isolated hematuria | 8 (2.4%) | 72 (3.4%) | |
| eGFR mL/min/1.73 m2 | median 39.3 (range 2.5–161.6) | median 66.8 (range 2.7–252) | <0.001 |
| eGFR ≥ 60 mL/min/1.73 m2 | 92 (26.1%) | 1194 (53.9%) | <0.001 |
| eGFR 30–59 mL/min/1.73 m2 | 113 (32.1%) | 548 (24.8%) | |
| eGFR 15–29 mL/min/1.73 m2 | 73 (20.7%) | 238 (10.8%) | |
| eGFR < 15 mL/min/1.73 m2 | 74 (21%) | 234 (10.5%) | |
| Duration of symptoms < 3 months | 165 (46.9%) | 847 (38.3%) | 0.002 |
| Duration of symptoms ≥3 months | 187 (53.1%) | 1367 (61.7%) | |
| Hypertension | 287 (84.2%) | 1398 (67.1%) | <0.001 |
| Diabetes | 64 (18.5%) | 160 (7.5%) | <0.001 |
| Steroid treatment before the biopsy | 59 (17.5%) | 491 (23.7%) | 0.012 |
| Other immunosuppressive treatment during pre-biopsy follow-up | 16 (4.8%) | 187 (9.0%) | 0.008 |
Renal biopsy diagnoses by age
| Diagnosis | Elderly (aged ≥65) ( | Younger (aged 18–64) ( |
|
|---|---|---|---|
| MGN | 64 (18.2%) | 227 (10.3%) | <0.001 |
| FSGS | 61 (17.3%) | 339 (15.3%) | 0.342 |
| Amyloidosis | 49 (13.9%) | 82 (3.7%) | <0.001 |
|
| 45 (12.8%) | 150 (6.8%) | <0.001 |
| IgAN | 33 (9.4%) | 604 (27.3%) | <0.001 |
| Crescentic GN (types I,II,III) | 31 (8.8%) | 109 (4.9%) | 0.005 |
| MCD | 22 (6.3%) | 132 (6%) | 0.809 |
| DKD | 16 (4.6%) | 62 (2.9%) | 0.100 |
| Unclassified lesions | 14 (4%) | 92 (4.2%) | 1.000 |
| Tubulointerstitial nephritis | 9 (2.6%) | 34 (1.5%) | 0.177 |
| Membrano-proliferative GN | 8 (2.3%) | 67 (3%) | 0.608 |
| Arterionephrosclerosis (hypertensive nephropathy and aging nephropathy) | 6 (1.7%) | 18 (0.8%) | 0.128 |
| MGA | 6 (1.7%) | 79 (3.6%) | 0.077 |
| End-stage kidney | 6 (1.7%) | 39 (1.8%) | 1.000 |
| LN | 5 (1.4%) | 191 (8.6%) | <0.001 |
| LCDD/HCDD | 4 (1.1%) | 6 (0.3%) | 0.037 |
| Acute tubular injury/necrosis | 4 (1.1%) | 8 (0.4%) | 0.070 |
| Thrombotic microangiopathy | 3 (0.9%) | 39 (1.8%) | 0.263 |
| Normal kidney morphology | 2 (0.6%) | 29 (1.3%) | 0.303 |
| TBMD | 1 (0.3%) | 40 (1.8%) | 0.036 |
The table encompasses only the diagnoses which were made in at least 1% of individuals in any of the two cohorts studied
Fig. 1Frequency (a) and relative frequency (b) distribution of selected kidney biopsy based diagnoses according to age of disease onset
Distribution of renal biopsy diagnoses among elderly and younger adult patients with nephrotic range proteinuria
| Nephrotic range proteinuria with hematuria |
| Nephrotic range proteinuria without hematuria |
| Nephrotic range proteinuria with or without hematuria |
| ||||
|---|---|---|---|---|---|---|---|---|---|
| Renal pathology | ≥65 ( | 18–64 ( | ≥65 ( | 18–64 ( | ≥65 ( | 18–64 ( | |||
| MGN | 22 (30.1%) | 49 (10.6%) | <0.001 | 25 (21.7%) | 106 (23.4%) | 0.804 | 47 (25.0%) | 155 (16.9%) | 0.013 |
| FSGS | 15 (20.6%) | 79 (17.1%) | 0.508 | 23 (20.0%) | 81 (17.9%) | 0.591 | 38 (20.2%) | 160 (17.5%) | 0.404 |
| Amyloidosis | 9 (12.3%) | 13 (2.8%) | 0.001 | 29 (25.2%) | 44 (9.7%) | <0.001 | 38 (20.2%) | 57 (6.2%) | <0.001 |
|
| 7 (9.6%) | 31 (6.7%) | 0.336 | 3 (2.6%) | 4 (0.9%) | 0.151 | 10 (5.3%) | 35 (3.8%) | 0.317 |
| IgAN | 6 (8.2%) | 114 (24.7%) | 0.001 | 4 (3.5%) | 39 (8.6%) | 0.075 | 10 (5.3%) | 154 (16.8%) | <0.001 |
| MCD | 5 (6.9%) | 30 (6.5%) | 0.804 | 11 (9.6%) | 84 (18.5%) | 0.025 | 16 (8.5%) | 114 (12.5%) | 0.137 |
| Membrano-proliferative GN | 5 (6.9%) | 30 (6.5%) | 0.804 | 1 (0.9%) | 11 (2.4%) | 0.475 | 6 (3.2%) | 41 (4.5%) | 0.553 |
| DKD | 2 (2.7%) | 26 (5.6%) | 0.405 | 13 (11.3%) | 23 (5.1%) | 0.029 | 15 (8.0%) | 49 (5.4%) | 0.170 |
| LN | 1 (1.4%) | 51 (11.1%) | 0.005 | 0 | 23 (5.1%) | 0.007 | 1 (0.5%) | 74 (8.1%) | <0.001 |
| End-stage kidney | 1 (1.4%) | 4 (0.9%) | 0.522 | 1 (0.9%) | 8 (1.8%) | 0.695 | 2 (1.1%) | 12 (1.3%) | 1.000 |
| Arterionephrosclerosis | 1 (1.4%) | 2 (0.4%) | 0.357 | 1 (0.9%) | 5 (1.1%) | 1.000 | 2 (1.1%) | 7 (0.8%) | 0.655 |
| MGA | 0 | 3 (0.7%) | 1.000 | 1 (0.9%) | 11 (2.4%) | 0.475 | 1 (0.5%) | 15 (1.6%) | 0.498 |
| Thrombotic microangiopathy | 0 | 9 (2.0%) | 0.618 | 1 (0.9%) | 6 (1.3%) | 1.000 | 1 (0.5%) | 15 (1.6%) | 0.498 |
| Unclassified lesions | 0 | 13 (2.8%) | 0.232 | 3 (2.6%) | 14 (3.1%) | 1.000 | 3 (1.6%) | 27 (3.0%) | 0.458 |
Distribution of renal biopsy diagnoses among elderly and younger patients with non-nephrotic range proteinuria
| Non-nephrotic range proteinuria with hematuria |
| Non-nephrotic range proteinuria without hematuria |
| Non-nephrotic range proteinuria with or without hematuria |
| ||||
|---|---|---|---|---|---|---|---|---|---|
| Renal pathology | ≥65 | 18–64 ( | ≥65 | 18–64 ( | ≥65 | 18–64 ( | |||
|
| 25 (32.9%) | 92 (11.7%) | <0.001 | 4 (6.9%) | 7 (2.1%) | 0.067 | 29 (21.6%) | 99 (8.8%) | <0.001 |
| IgAN | 15 (19.7%) | 336 (42.7%) | <0.001 | 5 (8.6%) | 74 (22.6%) | 0.013 | 20 (14.9%) | 413 (36.7%) | <0.001 |
| FSGS | 11 (14.5%) | 97 (12.3%) | 0.586 | 12 (20.7%) | 65 (19.8%) | 0.860 | 23 (17.2%) | 163 (14.5%) | 0.439 |
| Unclassified lesions | 7 (9.2%) | 29 (3.7%) | 0.032 | 3 (5.2%) | 24 (7.3%) | 0.781 | 10 (7.5%) | 53 (4.7%) | 0.204 |
| MGN | 4 (5.3%) | 27 (3.4%) | 0.342 | 10 (17.2%) | 40 (12.2%) | 0.292 | 14 (10.5%) | 67 (6.0%) | 0.046 |
| LN | 2 (2.6%) | 73 (9.3%) | 0.049 | 2 (3.5%) | 28 (8.5%) | 0.285 | 4 (3.0%) | 102 (9.1%) | 0.013 |
| Tubulointerstitial nephritis | 2 (2.6%) | 4 (0.5%) | 0.091 | 4 (6.9%) | 10 (3.1%) | 0.242 | 6 (4.5%) | 16 (1.4%) | 0.023 |
| LCDD/HCDD | 2 (2.6%) | 2 (0.3%) | 0.041 | 1 (1.7%) | 1 (0.3%) | 0.278 | 3 (2.2%) | 3 (0.3%) | 0.019 |
| Membrano-proliferative GN | 2 (2.6%) | 15 (1.9%) | 0.656 | 0 | 9 (2.7%) | 0.366 | 2 (1.5%) | 24 (2.1%) | 1.000 |
| End-stage kidney | 2 (2.6%) | 18 (2.3%) | 0.694 | 2 (3.5%) | 7 (2.1%) | 0.630 | 4 (3%) | 25 (2.2%) | 0.540 |
| TBMD | 1 (1.3%) | 23 (2.9%) | 0.715 | 0 | 2 (0.6%) | 1.000 | 1 (0.8%) | 25 (2.2%) | 0.513 |
| MCD | 1 (1.3%) | 5 (0.6%) | 0.426 | 4 (6.9%) | 8 (2.4%) | 0.089 | 5 (3.7%) | 13 (1.2%) | 0.035 |
| Amyloidosis | 1 (1.3%) | 7 (0.9%) | 0.523 | 8 (13.8%) | 15 (4.6%) | 0.013 | 9 (6.7%) | 23 (2.1%) | 0.005 |
| MGA | 0 | 31 (3.9%) | 0.102 | 1 (1.7%) | 16 (4.9%) | 0.281 | 1 (0.8%) | 48 (4.3%) | 0.046 |
| DKD | 0 | 8 (1.0%) | 1.000 | 1 (1.7%) | 5 (1.5%) | 1.000 | 1 (0.8%) | 13 (1.2%) | 1.000 |
| Thrombotic microangiopathy | 0 | 10 (1.3%) | 1.000 | 1 (1.7%) | 9 (2.7%) | 1.000 | 1 (0.8%) | 20 (1.8%) | 0.718 |
| Arterionephrosclerosis | 0 | 2 (0.3%) | 1.000 | 2 (3.5%) | 6 (1.8%) | 0.344 | 2 (1.5%) | 8 (0.7%) | 0.289 |
| Normal kidney morphology | 0 | 12 (1.5%) | 0.614 | 0 | 2 (0.6%) | 1.000 | 0 | 14 (1.3%) | 0.385 |
| Alport syndrome | 0 | 8 (1.0%) | 1.000 | 0 | 2 (0.6%) | 1.000 | 0 | 10 (0.9%) | 1.000 |
Renal biopsy diagnoses among patients with diabetes
| Patients with diabetes | Kidney biopsy diagnosis | |||
|---|---|---|---|---|
| Diabetic kidney disease absent | Diabetic kidney disease present | Coincidence of diabetic kidney disease and other nephropathy |
| |
| ≥ 65 ( | 48 (75.0%) | 11 (17.0%) | 4 (6.0%)a | 0.612 |
| 18–64 ( | 98 (61.3%) | 52 (32.5%) | 10 (6.3%)b | |
a2 cases of MGN, 1case of MCD and 1 case of IgAN
b6 cases of IgA-N, 1 case of LCDD, 1case of MCD, 2 cases of MGN